DB
MBRX icon

Danske Bank’s Moleculin Biotech MBRX Stock Holding History

Danske Bank’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5 Hold
2
– – ﹤0.01% 1107
2025
Q4 		$7 Buy
+2
New +$19 ﹤0.01% 1492
2024
Q4 		– Hold
0
– -$6 – 1548
2024
Q3 		– Hold
0
– – – 1546

Other funds holding MBRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM

Danske Bank's MBRX Position: Q1 2026 in Review

Danske Bank held its Moleculin Biotech (MBRX) position steady in Q1 2026 at 2 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

Danske Bank first reported a position in MBRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $7 in Q4 2025. 20 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

  • Danske Bank held 2 shares of Moleculin Biotech worth $5 as of Q1 2026.
  • Danske Bank left its Moleculin Biotech share count unchanged in Q1 2026.
  • Moleculin Biotech made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1107 holding.
  • Danske Bank first reported a position in Moleculin Biotech in Q4 2025 and has held it in 2 quarters since.
  • Danske Bank's Moleculin Biotech position peaked at $7 in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.